Response After Single Treatment with Canakinumab Predicts Which Patients Will Benefit Most

New analysis from CANTOS finds that measuring hsCRP levels after one dose of canakinumab can identify individuals likely to see greatest improvements from continued treatment.
Source: BWH for Journalists - Category: Research Source Type: news
More News: Research